SC-236

DB14059

small molecule experimental investigational

Deskripsi

SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) L2964 that has been studied in cancer therapy A33375, lower back pain A33376, and inflammation A33373, A33374,L2962, A33377.

Struktur Molekul 2D

Berat 401.79
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Long plasma half-life [A28366].
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

1386 Data
Amlodipine SC-236 may decrease the antihypertensive activities of Amlodipine.
Phentermine The risk or severity of hypertension can be increased when Phentermine is combined with SC-236.
Midodrine The risk or severity of hypertension can be increased when Midodrine is combined with SC-236.
Eletriptan The risk or severity of hypertension can be increased when Eletriptan is combined with SC-236.
Isoetharine The risk or severity of hypertension can be increased when Isoetharine is combined with SC-236.
Ziprasidone The risk or severity of hypertension can be increased when Ziprasidone is combined with SC-236.
Methysergide The risk or severity of hypertension can be increased when Methysergide is combined with SC-236.
Cabergoline The risk or severity of hypertension can be increased when Cabergoline is combined with SC-236.
Zolmitriptan The risk or severity of hypertension can be increased when Zolmitriptan is combined with SC-236.
Dihydroergotamine The risk or severity of hypertension can be increased when Dihydroergotamine is combined with SC-236.
Methylergometrine The risk or severity of hypertension can be increased when Methylergometrine is combined with SC-236.
Norepinephrine The risk or severity of hypertension can be increased when Norepinephrine is combined with SC-236.
Mirtazapine The risk or severity of hypertension can be increased when Mirtazapine is combined with SC-236.
Phenylephrine The risk or severity of hypertension can be increased when Phenylephrine is combined with SC-236.
Phenylpropanolamine The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with SC-236.
Promazine The risk or severity of hypertension can be increased when Promazine is combined with SC-236.
Droperidol The risk or severity of hypertension can be increased when Droperidol is combined with SC-236.
Doxapram The risk or severity of hypertension can be increased when Doxapram is combined with SC-236.
Atropine The risk or severity of hypertension can be increased when Atropine is combined with SC-236.
Lisuride The risk or severity of hypertension can be increased when Lisuride is combined with SC-236.
Linezolid The risk or severity of hypertension can be increased when Linezolid is combined with SC-236.
Metaraminol The risk or severity of hypertension can be increased when Metaraminol is combined with SC-236.
Furazolidone The risk or severity of hypertension can be increased when Furazolidone is combined with SC-236.
Epinephrine The risk or severity of hypertension can be increased when Epinephrine is combined with SC-236.
Thioridazine The risk or severity of hypertension can be increased when Thioridazine is combined with SC-236.
Ergotamine The risk or severity of hypertension can be increased when Ergotamine is combined with SC-236.
Nicergoline The risk or severity of hypertension can be increased when Nicergoline is combined with SC-236.
Sufentanil The risk or severity of hypertension can be increased when Sufentanil is combined with SC-236.
Methoxamine The risk or severity of hypertension can be increased when Methoxamine is combined with SC-236.
Risperidone The risk or severity of hypertension can be increased when Risperidone is combined with SC-236.
Tranylcypromine The risk or severity of hypertension can be increased when Tranylcypromine is combined with SC-236.
Isoflurane The risk or severity of hypertension can be increased when Isoflurane is combined with SC-236.
Propiomazine The risk or severity of hypertension can be increased when Propiomazine is combined with SC-236.
Alfentanil The risk or severity of hypertension can be increased when Alfentanil is combined with SC-236.
Minaprine The risk or severity of hypertension can be increased when Minaprine is combined with SC-236.
Orciprenaline The risk or severity of hypertension can be increased when Orciprenaline is combined with SC-236.
Propofol The risk or severity of hypertension can be increased when Propofol is combined with SC-236.
Phenmetrazine The risk or severity of hypertension can be increased when Phenmetrazine is combined with SC-236.
Trifluoperazine The risk or severity of hypertension can be increased when Trifluoperazine is combined with SC-236.
Pseudoephedrine The risk or severity of hypertension can be increased when Pseudoephedrine is combined with SC-236.
Benzphetamine The risk or severity of hypertension can be increased when Benzphetamine is combined with SC-236.
Ritodrine The risk or severity of hypertension can be increased when Ritodrine is combined with SC-236.
Flupentixol The risk or severity of hypertension can be increased when Flupentixol is combined with SC-236.
Remifentanil The risk or severity of hypertension can be increased when Remifentanil is combined with SC-236.
Bitolterol The risk or severity of hypertension can be increased when Bitolterol is combined with SC-236.
Oxymetazoline The risk or severity of hypertension can be increased when Oxymetazoline is combined with SC-236.
Diethylpropion The risk or severity of hypertension can be increased when Diethylpropion is combined with SC-236.
Salmeterol The risk or severity of hypertension can be increased when Salmeterol is combined with SC-236.
Naratriptan The risk or severity of hypertension can be increased when Naratriptan is combined with SC-236.
Formoterol The risk or severity of hypertension can be increased when Formoterol is combined with SC-236.
Frovatriptan The risk or severity of hypertension can be increased when Frovatriptan is combined with SC-236.
Methoxyflurane The risk or severity of hypertension can be increased when Methoxyflurane is combined with SC-236.
Selegiline The risk or severity of hypertension can be increased when Selegiline is combined with SC-236.
Ergoloid mesylate The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with SC-236.
Isoprenaline The risk or severity of hypertension can be increased when Isoprenaline is combined with SC-236.
Arbutamine The risk or severity of hypertension can be increased when Arbutamine is combined with SC-236.
Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with SC-236.
Halothane The risk or severity of hypertension can be increased when Halothane is combined with SC-236.
Moclobemide The risk or severity of hypertension can be increased when Moclobemide is combined with SC-236.
Pergolide The risk or severity of hypertension can be increased when Pergolide is combined with SC-236.
Desflurane The risk or severity of hypertension can be increased when Desflurane is combined with SC-236.
Bromocriptine The risk or severity of hypertension can be increased when Bromocriptine is combined with SC-236.
Finasteride The risk or severity of hypertension can be increased when Finasteride is combined with SC-236.
Aripiprazole The risk or severity of hypertension can be increased when Aripiprazole is combined with SC-236.
Isocarboxazid The risk or severity of hypertension can be increased when Isocarboxazid is combined with SC-236.
Ergometrine The risk or severity of hypertension can be increased when Ergometrine is combined with SC-236.
Lisdexamfetamine The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with SC-236.
Fenoterol The risk or severity of hypertension can be increased when Fenoterol is combined with SC-236.
Pirbuterol The risk or severity of hypertension can be increased when Pirbuterol is combined with SC-236.
Ephedra sinica root The risk or severity of hypertension can be increased when Ephedra sinica root is combined with SC-236.
Ephedrine The risk or severity of hypertension can be increased when Ephedrine is combined with SC-236.
Mephentermine The risk or severity of hypertension can be increased when Mephentermine is combined with SC-236.
Procaterol The risk or severity of hypertension can be increased when Procaterol is combined with SC-236.
Yohimbine The risk or severity of hypertension can be increased when Yohimbine is combined with SC-236.
Methotrimeprazine The risk or severity of hypertension can be increased when Methotrimeprazine is combined with SC-236.
Clenbuterol The risk or severity of hypertension can be increased when Clenbuterol is combined with SC-236.
Bambuterol The risk or severity of hypertension can be increased when Bambuterol is combined with SC-236.
MMDA The risk or severity of hypertension can be increased when MMDA is combined with SC-236.
Midomafetamine The risk or severity of hypertension can be increased when Midomafetamine is combined with SC-236.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with SC-236.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with SC-236.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with SC-236.
Tenamfetamine The risk or severity of hypertension can be increased when Tenamfetamine is combined with SC-236.
Chlorphentermine The risk or severity of hypertension can be increased when Chlorphentermine is combined with SC-236.
Dextroamphetamine The risk or severity of hypertension can be increased when Dextroamphetamine is combined with SC-236.
Phendimetrazine The risk or severity of hypertension can be increased when Phendimetrazine is combined with SC-236.
Solifenacin The risk or severity of hypertension can be increased when Solifenacin is combined with SC-236.
Periciazine The risk or severity of hypertension can be increased when Periciazine is combined with SC-236.
Acepromazine The risk or severity of hypertension can be increased when Acepromazine is combined with SC-236.
Thioproperazine The risk or severity of hypertension can be increased when Thioproperazine is combined with SC-236.
Zuclopenthixol The risk or severity of hypertension can be increased when Zuclopenthixol is combined with SC-236.
Epicaptopril The risk or severity of hypertension can be increased when Epicaptopril is combined with SC-236.
Clorgiline The risk or severity of hypertension can be increased when Clorgiline is combined with SC-236.
1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with SC-236.
Iproniazid The risk or severity of hypertension can be increased when Iproniazid is combined with SC-236.
Nialamide The risk or severity of hypertension can be increased when Nialamide is combined with SC-236.
Lysergic acid diethylamide The risk or severity of hypertension can be increased when Lysergic acid diethylamide is combined with SC-236.
Dronedarone The risk or severity of hypertension can be increased when Dronedarone is combined with SC-236.
Flibanserin The risk or severity of hypertension can be increased when Flibanserin is combined with SC-236.
Iloperidone The risk or severity of hypertension can be increased when Iloperidone is combined with SC-236.

Target Protein

Cyclooxygenase 2 PTGS2
Prostaglandin G/H synthase 2 PTGS2
Nuclear factor NF-kappa-B complex NFKB2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17822719
    Kim SJ, Jeong HJ, Moon PD, Myung NY, Kim MC, Kang TH, Lee KM, Park RK, So HS, Kim EC, An NH, Um JY, Kim HM, Hong SH: The COX-2 inhibitor SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model. Life Sci. 2007 Aug 23;81(11):863-72. doi: 10.1016/j.lfs.2007.06.027. Epub 2007 Sep 5.
  • PMID: 15784648
    Kim SJ, Jeong HJ, Choi IY, Lee KM, Park RK, Hong SH, Kim HM: Cyclooxygenase-2 inhibitor SC-236 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l benzenesulfonamide] suppresses nuclear factor-kappaB activation and phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and c-Jun N-terminal kinase in human mast cell line cells. J Pharmacol Exp Ther. 2005 Jul;314(1):27-34. doi: 10.1124/jpet.104.082792. Epub 2005 Mar 22.
  • PMID: 14699495
    Wong BC, Jiang XH, Lin MC, Tu SP, Cui JT, Jiang SH, Wong WM, Yuen MF, Lam SK, Kung HF: Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Gastroenterology. 2004 Jan;126(1):136-47.
  • PMID: 11192259
    Deleo TA, Hashizume H, Rutkowski MD, Weinstein TN: Cyclooxygenase-2 inhibitor SC-236 attenuates mechanical allodynia following nerve root injury in rats. J Orthop Res. 2000 Nov;18(6):977-82. doi: 10.1002/jor.1100180618.
  • PMID: 12203123
    Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB, Wong BC: Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene. 2002 Sep 5;21(39):6113-22. doi: 10.1038/sj.onc.1205778.
  • PMID: 9135032
    Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, AndersonGD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-ylbenze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347-65.
  • PMID: 16718813
    Dai Y, Wang WH: Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol. 2006 May 14;12(18):2884-9.
  • PMID: 12606945
    Wong BC, Jiang Xh, Fan XM, Lin MC, Jiang SH, Lam SK, Kung HF: Suppression of RelA/p65 nuclear translocation independent of IkappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene. 2003 Feb 27;22(8):1189-97. doi: 10.1038/sj.onc.1206234.
Textbook
  • Randall E. Harris (2002). COX-2 Blockade in Cancer Prevention and Therapy. Humana Press.
  • Luka Milas, K. K Ang, C. Nieder (2003). Modification of Radiation Response: Cytokines, Growth Factors, and Other Biological Targets (Medical Radiology). Springer.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul